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Abstract
Background: Bacteriophages specific for Yersinia pestis are routinely used for plague diagnostics and could be an alternative
to antibiotics in case of drug-resistant plague. A major concern of bacteriophage therapy is the emergence of phage-
resistant mutants. The use of phage cocktails can overcome this problem but only if the phages exploit different receptors.
Some phage-resistant mutants lose virulence and therefore should not complicate bacteriophage therapy.
Methodology/Principal Findings: The purpose of this work was to identify Y. pestis phage receptors using site-directed
mutagenesis and trans-complementation and to determine potential attenuation of phage-resistant mutants for mice. Six
receptors for eight phages were found in different parts of the lipopolysaccharide (LPS) inner and outer core. The receptor
for R phage was localized beyond the LPS core. Most spontaneous and defined phage-resistant mutants of Y. pestis were
attenuated, showing increase in LD50 and time to death. The loss of different LPS core biosynthesis enzymes resulted in the
reduction of Y. pestis virulence and there was a correlation between the degree of core truncation and the impact on
virulence. The yrbH and waaA mutants completely lost their virulence.
Conclusions/Significance: We identified Y. pestis receptors for eight bacteriophages. Nine phages together use at least
seven different Y. pestis receptors that makes some of them promising for formulation of plague therapeutic cocktails. Most
phage-resistant Y. pestis mutants become attenuated and thus should not pose a serious problem for bacteriophage
therapy of plague. LPS is a critical virulence factor of Y. pestis.
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Introduction
Yersinia pestis is the causative agent of plague circulating in
natural foci among multiple species of wild animals. Humans
usually become infected via fleabites. Plague has killed many
millions of people during three pandemics and is now recognized
as a re-emerging disease. Y. pestis is considered a biothreat agent
belonging to the most dangerous group of pathogens, CDC
Category A [1–3]. Multiple drug-resistant strains of Y. pestis
have been isolated from patients with bubonic plague. One of
them carried genes of high-level resistance to 12 antibiotics,
including virtually all of the drugs commonly used for plague
prophylaxis and treatment [4]. The emergence of multidrug-
resistant strains requires the immediate development of alternative
methods of plague therapy including the possible use of
bacteriophages [5]. There are more and more publications on
successful bacteriophage treatment of various experimental and
veterinary infections and some promising clinical trials in humans
(for reviews, see [6–8]).
Many bacteriophages (phages) are capable of lysing Y. pestis
[9–21], and some of them have a high potential to be used for
antibacterial treatment of plague. Several phages have been shown
to be highly lytic and specific for Y. pestis and are routinely used for
diagnosis of plague [22,23]. They include the Pokrovskaya
[9,14,23,24], QA1122 [10,18,22,25], L-413C [14,19,23,24], and
Yep-phi [21] phages. The QA1122 [26,27] and L-413C [27]
phages have been recently used for the development of improved
Y. pestis detection techniques using fluorescently labeled QA1122
[26] or amplification of phage DNA monitored by qPCR [27].
The genomes of QA1122 [18], L-413C [19], and Yep-phi [21]
have been sequenced and no genes potentially detrimental for
mammals were found in them.
A major concern regarding the use of phages in the treatment of
infectious diseases still remains the emergence of phage-resistant
mutants [28–30]. This resistance can arise due to the alteration or
loss of the bacterial cell surface receptor, blocking the receptor by
the bacterial extracellular matrix, inhibition of phage DNA
penetration, production of modified restriction endonucleases
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development [31]. Mutations affecting phage receptors represent
the most frequent cause of phage resistance [31–33]. Phage
receptors are diverse bacterial surface-exposed molecules including
many outer membrane proteins, sugar residues in the O antigen or
lipopolysaccharide (LPS) core, teichoic acids, polysaccharides of the
capsule or slime layer, or components of flagella and pili [32,33]. In
pathogenic bacteria, many phage receptors are essential virulence
factors, some of which were identified through the selection of
phage-resistant mutations. The receptors include capsular polysac-
charides [34–36], adhesion and invasion factors [37–39], a protein
involved in intracellular growth [40], and, very commonly, different
components of LPS [41–47]. If a phage receptor lies in a surface
structure important for virulence, the phage-resistant mutants
resulting from a loss or alteration of the receptor will be avirulent or
attenuated. Such mutant bacterial clones will then be eliminated
from the host by the immune system and therefore should not
present a problem if they arise during bacteriophage treatment
[29,34,35,38]. Another way to overcome the problem of phage
resistance is to use therapeutic phage cocktails, which requires
avoiding cross-resistance, i.e. bacterial mutants resistant to one
phage must remain sensitive to the other components of the cocktail
[29,30,48]. Thus, ideally, bacteriophages comprising the cocktail
should employ different bacterial cell surface receptors [29,48].
The purpose of this work was to study spontaneous and site-
directed (non-polar) mutants of Y. pestis resistant to various
bacteriophages, to identify phage receptors and to determine if
phage-resistant mutants are impaired in virulence for mice. Nine
phages capable of lysing Y. pestis were tested: L-413C, P2 vir1,
QJA1, QA1122, Pokrovskaya, T7Yp, Y, PST, and R. We identified
six receptors for eight bacteriophages in different parts of the LPS
core. Altogether, the phages used at least seven different receptors
in Y. pestis. Therefore, one can formulate a plague therapeutic
cocktail containing several highly lytic phages exploiting different
Y. pestis cell surface receptors. Most of the Y. pestis phage-resistant
mutants were attenuated and thus should not present a problem
for phage therapy. A direct correlation was observed between the
length of the LPS core and virulence. The yrbH and waaA mutants
were completely avirulent and thus LPS was shown to be a critical
virulence factor of Y. pestis.
Materials and Methods
Ethics statement
Animal studies were conducted in compliance with the Animal
Welfare Act and other federal, state and local laws and regulations
regarding animal work, in a facility accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care
International. All experiments with mice were performed under
the animal use protocol approved by the Walter Reed Army
Institute of Research Institutional Animal Care and Use
Committee (Protocol #IB05-09).
Bacteria, bacteriophages and growth media
Bacterial strains and bacteriophages used in this work are listed
in Tables 1 and 2, respectively. High-concentration stocks of the
QA1122, Pokrovskaya, Y, and T7Yp phages were prepared using Y.
pestis CO92 Pgm
2 cultured at 28uC by the low multiplicity of
infection method [66]. The same technique was used for large-
scale isolation of the PST and R phages but they were grown on Y.
pseudotuberculosis PB1. Finally, this method was used to propagate
T7 on E. coli C600 at 37uC. The L-413C, QJA1, and P2 vir1 phage
stocks were prepared on Y. pestis CO92 Pgm
2 as described
previously [19] using different temperatures of incubation, 28uC
for L-413C and QJA1 or 37uC for P2 vir1. Bacteria and
bacteriophages were grown in liquid Brain Heart Infusion (BHI)
medium (Becton-Dickinson, Franklin Lakes, New Jersey, USA) or
on BHI plates containing 1.5% and 0.7% Bacto Agar (Becton-
Dickinson) except E. coli strains, which were grown in LB broth
(Becton-Dickinson) or on LB agar plates. The slants with tryptose
blood agar (Becton-Dickinson) containing 5% defibrinated sheep
blood (Lampire Biological Laboratories, Pipersville, Pennsylvania,
USA) were used for streaking Y. pestis frozen stocks to prepare the
challenge suspensions in animal experiments [67].
Bacteriophage assays
SM buffer [66] was used for bacteriophage storage and
dilutions. Phage plaque assays were performed by the double-
layer agar method as described earlier [66] with overnight
incubation for L-413C, P2 vir1, QJA1, Y, PST, and R, or 5–6 h
incubation for QA1122, Pokrovskaya, T7, and T7Yp. Plaquing
(plating) efficiency tests were done as described previously [19]
using an incubator temperature of 28uC. Phage adsorption
experiments were performed according to [19].
Isolation of spontaneous phage-resistant mutants and
determination of the mutation frequencies
Spontaneous Y. pestis mutants resistant to bacteriophages were
isolated from avirulent strains CO92 Pgm
2, KIM D27, and
A1122, as well as from wild-type virulent CO92 by plating on
double-layer agar with the phage, 10
9 PFU (plaque-forming unit)
per plate. To determine the mutation frequencies per cell per
generation, ten isolated colonies were picked out from each strain,
inoculated into ten tubes with BHI, grown with agitation until
approximate concentration of 10
9 CFU/ml (colony-forming unit)
and diluted in ten-fold increments down to 10
27. 0.1-ml aliquots
from the 10
0–10
23 dilutions were inoculated onto the double-layer
plates and were incubated at 28uC for six days because some of the
phage-resistant mutants grow very slowly. Simultaneously, 0.1-ml
aliquots of 10
25,1 0
26, and 10
27 dilutions were plated on BHI
agar without phage (three plates for each dilution), for determi-
nation of CFU numbers. To calculate mutation frequencies, mean
numbers of mutants in one ml of culture were divided by mean
total numbers of live bacterial cells. The phage resistant colonies
were picked up and purified by two passages on double-layer
plates with the phage and were used in further experiments.
Site-directed mutagenesis
Site-directed mutagenesis of Y. pestis CO92 LPS genes was
performed by one-step PCR-mediated in-frame replacement with
the Tn903 kanamycin cassette as described earlier [68]. This
kanamycin resistance gene, aph(39)-Ia [69], does not provide cross-
resistance to streptomycin and gentamicin [70]; the procedure was
approved by the WRAIR Institutional Biosafety Committee (the
protocol MUA #125-a, June 14, 2004) and by CDC (Memoran-
dum of February 25, 2008). Primers used for mutagenesis and
verifying the correctness of replacement were designed using
NetPrimer online program (Premier Biosoft International, http://
www.premierbiosoft.com) and are listed in Table S1. The
mutagenesis primers were designed so that the replacements were
non-polar and preserved adjacent genes including ribosome-
binding sites intact.
Testing potential phenotypic alterations in Y. pestis
phage-resistant mutants
Spontaneous and induced Y. pestis phage-resistant mutants were
tested for plasmid content by the method of Kado and Liu [71], for
Y. pestis Phage-Resistant Mutants
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response on magnesium-oxalate agar plates [73], and for possible
loss of natural polymyxin resistance associated with rough type of
LPS on BHI agar with polymyxin B (10 and 150 U/ml; Sigma-
Aldrich, St. Louis, Missouri, USA) and without the antibiotic.
Molecular cloning and trans-complementation
Y. pestis LPS biosynthesis genes were cloned into a pBAD-
TOPO vector using pBAD TOPOH TA Expression Kit (Invitro-
gen) according to recommendations of the supplier. Primers for
PCR cloning are presented in Table S2. All genes were cloned
Table 1. Bacterial strains used in this work.
Strain Relevant characteristics Source/reference
Yersinia pestis:
CO92 Pgm
2 Attenuated
a, Pmx
r (polymyxin B resistant) Lab collection [49]
CO92 Pgm
2 lpxM Km
r-cassette replacement of YPO2063 (lpxM)
b gene, Pmx
r This work
CO92 Pgm
2 yrbH Km
r-cassette replacement of YPO3577 (yrbH) gene, Pmx
s This work
CO92 Pgm
2 yrbH (pBAD
c) Transformed with a pBAD vector (Ap
r, Invitrogen) This work
CO92 Pgm
2 yrbH (pYrbH) pYrbH is pBAD with cloned yrbH This work
CO92 Pgm
2 waaA Km
r-cassette replacement of YPO0055 (waaA) gene, Pmx
s This work
CO92 Pgm
2 waaA (pBAD) Transformed with pBAD This work
CO92 Pgm
2 waaA (pWaaA) pWaaA is pBAD with cloned waaA This work
CO92 Pgm
2 hldE Km
r-cassette replacement of YPO0654 gene, Pmx
s This work
CO92 Pgm
2 hldE (pBAD) Transformed with pBAD This work
CO92 Pgm
2 hldE (pHldE) P654 is pBAD with cloned YPO0654 This work
CO92 Pgm
2 waaF Km
r-cassette replacement of YPO0057 (waaF) gene, Pmx
s This work
CO92 Pgm
2 waaF (pBAD) Transformed with pBAD This work
CO92 Pgm
2 waaF (pWaaF) pWaaF is pBAD with cloned waaF This work
CO92 Pgm
2 waaL Km
r-cassette replacement of YPO0417 (waaL) gene, Pmx
r This work
CO92 Pgm
2 waaL (pBAD) Transformed with pBAD This work
CO92 Pgm
2 waaL (pWaaL) pWaaL is pBAD with cloned waaL This work
CO92 Pgm
2 wabD Km
r-cassette replacement of YPO0187 gene, Pmx
r This work
CO92 Pgm
2 wabC Km
r-cassette replacement of YPO0186 gene, Pmx
r This work
CO92 Fully virulent strain, from human case of pneumonic plague, Pmx
r Lab collection [52]
CO92 yrbH-1 Km
r-cassette replacement of YPO3577 (yrbH) gene, Pmx
s This work
CO92 yrbH-2 An independent yrbH mutant, Pmx
s This work
CO92 waaA-1 Km
r-cassette replacement of YPO0055 (waaA) gene, Pmx
s This work
CO92 waaA-2 An independent waaA mutant, Pmx
s This work
CO92 hldE Km
r-cassette replacement of YPO0654 gene, Pmx
s This work
CO92 waaF Km
r-cassette replacement of YPO0057 (waaF) gene, Pmx
s This work
CO92 waaL Km
r-cassette replacement of YPO0417 (waaL) gene, Pmx
r This work
CO92 S-2 Spontaneous L-413C-resistant mutant, Pmx
s This work
CO92 S-7 Spontaneous L-413C-resistant mutant, Pmx
r This work
KIM D27 KIM Pgm
2, attenuated
a, Pmx
r Lab collection [53]
A1122 Pgm
2 pCD1
2, attenuated
a, Pmx
r Lab collection [54]
Yersinia pseudotuberculosis:
PB1 Serovar IB Lab collection [55]
Escherichia coli:
C600 K-12 derivative; l– supE44 tonA21 (rk
+mk
+) Lab collection [56]
C600 pUTKm pUTKm
d is a Tn903 kan gene source [57] Lab collection
TOP10 DlacX74 deoR recA1 rpsL, endA1, nupG Invitrogen
C-520 ‘‘Restrictionless’’ P2 phage indicator strain R. Calendar
e [58]
aThese strains are attenuated due to a lack of pigmentation/siderophore yersiniabactin production genes and/or of pCD1 plasmid encoding type III secretion system
and virulence Yop proteins (for review, see [1]).
bY. pestis CO92 LPS gene designations are given according to [50,51].
cClones with a pBAD vector (Invitrogen, Carlsbad, California, USA) were used in trans-complementation experiments to exclude a possible impact of pBAD on LPS
expression and phage susceptibility.
dPlasmid pUTKm was used as a source of kanamycin cassette.
eDepartment of Molecular and Cell Biology, University of California, Berkeley, California, USA.
doi:10.1371/journal.pone.0025486.t001
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yrbH, which was cloned under the control of its own promoter, as
described elsewhere [74]. Two tandem stop codons (see Table S2)
were placed immediately upstream of the yrbH promoter to
prevent the expression of a truncated protein from the pBAD
arabinose promoter. The knockout mutants were cured of a
mutagenesis helper plasmid pKD46 [68] by growing at increased
temperature, at 38uC. The recombinant plasmids were introduced
into corresponding mutants using electroporation. All mutants
were also transformed with DNA of the intact pBAD (to exclude a
possible impact of the vector plasmid on LPS expression and
phage susceptibility). Transformants that acquired a recombinant
plasmid or the vector without an insert were tested for plaquing
efficiencies on the double-layer BHI plates supplemented with
10 mM of L-arabinose to induce the pBAD promoter, as well as
for the LPS size (see below).
SDS-PAGE analysis of LPS
The presence and size of LPS core in Y. pestis strains was
analyzed as described previously [74], with the following minor
modifications. Y. pestis strains were grown overnight at 28uCi n
BHI. After the lysis and deproteinization, LPS was visualized by
fluorescent staining using Pro-QH Emerald 300 Lipopolysaccha-
ride Gel Stain Kit (Invitrogen).
Infection of mice
Y. pestis strains for animal challenge experiments were isolated
from single colonies, tested for the presence of three virulence
plasmids [71], pigmentation [72], and low calcium response [73]
and kept at 280uC in BHI with 10% dimethyl sulfoxide. The
challenge culture suspensions were prepared from the frozen
stocks according to [67] but using normal saline instead of HIB
broth. Mouse lethality was determined following subcutaneous
inoculation of 100 ml saline containing each of various 10-fold
concentrations of Y. pestis into groups of ten 8-week-old female
BALB/c mice. The mice were observed twice a day until 14 days
postinfection. Median lethal doses (LD50) were calculated by the
method of Reed and Muench [75]. In addition to the number of
deaths, the mean time to death (MTD) was recorded.
Results
Spontaneous bacteriophage resistance mutations in Y.
pestis
First, we determined the frequencies of spontaneous mutations
resulting in resistance of Y. pestis towards four different phages, L-
413C, QA1122, Pokrovskaya, and Y (Table 3). Y. pestis CO92
showed different mutation frequencies to the L-413C, Pokrovs-
kaya, and Y phages. No QA1122-resistant mutations were
observed. Six independent mutants resistant to L-413C (two for
each of the three strains, CO92 Pgm
2, KIM D27, and A1122)
were isolated and their phenotypes tested. Five out of six clones
lost the native resistance to polymyxin B associated with the rough
form of Y. pestis LPS, suggesting LPS core damage [51,76]. Since
Table 2. Bacteriophages used in this work.
Bacteriophage Group Source Reference(s)
LPS residues critical for phage receptors
(determined in this work)
L-413C P2 Lab collection [14,19,23,24,27] GlcNAc
P2 vir1 P2 R. Calendar [59] GlcNAc
QJA1
a P2? Sewage This work Kdo/Ko
QA1122 T7 M.E. Schriefer
b [10,18,22,25–27] Kdo/Ko
T7 T7 I.J. Molineux
c [60] NA
d
T7Yp
e T7 T7 host range mutant This work HepI/Glc
Pokrovskaya ND
f B.B. Atshabar
g [9,14,23,24] HepII/HepIII
Y T3? ATCC [12,13] HepI/Glc
PST T2? ATCC [12,61–63] HepII/HepIII
R
h ND ATCC [12,15,63–65] Beyond LPS core
aPhage QJA1 isolated from sewage lyses multiple Y. pestis strains but not Y. pseudotuberculosis or E. coli K-12; it has some degree of homology to L-413C because its DNA
is amplified in qPCR with one of two tested pairs of primers specific for L-413C (A.A. Filippov, Y. He, and K.V. Sergueev, unpublished data).
bBacterial Diseases Branch, Division of Vector-Borne Infectious Disease, National Center for Zoonotic, Vector-Borne and Enteric Diseases, Centers for Disease Control and
Prevention, Ft. Collins, Colorado, USA.
cSection of Molecular Genetics and Microbiology, and Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, Texas, USA.
dNA, not applicable.
eT7Yp is a T7 host range mutant isolated on the lawn of Y. pestis CO92; T7Yp produces plaques on Y. pestis but not on Y. pseudotuberculosis or Yersinia enterocolitica and
has a low plaquing efficiency on E. coli K-12 (A.A. Filippov, Y. He, and K.V. Sergueev, unpublished data).
fND, not determined.
gKazakh Scientific Center for Quarantine and Zoonotic Diseases, Almaty, Kazakhstan.
hR phage (R stands for ‘‘Russian’’ [12]) was originally isolated and studied by R.I. Kotlyarova [64] and is also designated as the Kotlyarova phage. Pseudotuberculosis
diagnostic phages PST [63] and R [15] can lyse 92–100% of Y. pseudotuberculosis strains but are also active against the majority of Y. pestis strains.
doi:10.1371/journal.pone.0025486.t002
Table 3. Frequencies of Y. pestis spontaneous mutations to
bacteriophage resistance.
Y. pestis strain Mutation frequency of resistance to:
L-413C QA1122 Pokrovskaya Y
CO92 Pgm
2 1.2610
24 ,3.1610
210 5.5610
26 5.3610
27
KIM D27 1.1610
24 ,4.2610
210 NT
a NT
A1122 1.0610
24 NT NT NT
aNT, not tested.
doi:10.1371/journal.pone.0025486.t003
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pleiotropic effects on several phenotypic traits [77,78], we tested
L-413C-resistant mutants for plasmid content, pigmentation, and
low calcium response and observed no alterations in these traits in
comparison with the parental strains. All six mutants were found
to remain sensitive to QA1122.
Identification of bacteriophage receptors
To identify bacteriophage receptors, a series of defined non-
polar Y. pestis CO92 Pgm
2 mutants affected in genes encoding the
synthesis of different parts of LPS (Table 1) were obtained by one-
step knockout kanamycin cassette mutagenesis [68]. Several LPS
biosynthesis genes were cloned in a pBAD vector (Invitrogen) and
used for trans-complementation tests. Both knockout mutants and
trans-complemented clones were tested for susceptibility to nine
bacteriophages using comparative plaquing efficiency assays (see
Tables 4 and 5). Such approach has been recently successfully used
for identification of T7 receptor in E. coli K-12 [79]. We
additionally tested the knockout mutants for the efficiency of
phage adsorption in comparison with the parental strain CO92
Pgm
2 (Table 6). The results of mutagenesis were verified by PCR
(data not shown) and fluorescent staining of LPS that demon-
strated an increase in electrophoretic mobility or the loss of LPS
bands in the mutants (Fig. 1).
The fine structure of LPS in all kinds of Y. pestis knockout
mutants used in our work has been previously characterized in
details using mass spectroscopy analysis in strains KIM6 of bv.
Medievalis [80] (for the waaA and yrbH mutants) and 231 of bv.
Antiqua [51] (for the rest of mutants). We used BLAST analysis
[81] for comparison of 11 LPS biosynthesis proteins (YrbH,
WaaA, HldE, WaaF, WaaL, WabC, WabD, WecA, WaaQ,
WaaE, and WaaC) including all those, the genes for which were
knocked out in this work, in 23 published whole genome sequences
of Y. pestis strains of various biovars deposited in the NCBI
databases (http://www.ncbi.nlm.nih.gov/). They showed 100%
identity, or, in rare cases, 99% identity of amino acid sequences.
This suggested that the LPS core structure of diverse Y. pestis
strains is highly conserved and thus we could use the structural
data of other authors [51,80].
In contrast to the data of another group based on multi-step
suicide plasmid mutagenesis [78,82], in our experiments lpxM
(msbB) mutants with altered lipid A acylation were susceptible to
L-413C, as well as to eight other phages (Table 4). Mutations in
genes responsible for early steps of LPS core synthesis, yrbH and
waaA, resulted in the loss of both outer and inner LPS core [80]
(see Fig. 2). The coreless mutants had slower growth [80],
especially in early generations, and displayed resistance to eight
phages of the nine tested (Table 4), suggesting that the receptors
for these eight bacteriophages lie in the LPS core. Mutants affected
in carbohydrate residues of the main LPS core chain (hldE, waaF,
and waaL) were completely resistant to the L-413C and P2 vir1
phages (Table 4 and Fig. 2). The waaL mutants are deficient in O
antigen ligase, but in Y. pestis lacking O antigen the WaaL protein
Table 4. Plaquing efficiencies of various phages on Y. pestis CO92 LPS-affected mutants.
Y. pestis strain
a Efficiencies of plating
b
L-413C P2 vir1 QJA1 QA1122 Pokrovskaya T7Yp Y PST R
CO92 Pgm
2 (parental) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
lpxM 1.1 0.8 0.1 0.4 1.2 1.7 1.0 1.1 1.0
yrbH ,2.0610
212 ,5.0610
28 ,7.1610
210 1.2610
24 6.9610
212 1.1610
29 5.3610
29 ,7.1610
212 0.1
waaA ,2.0610
212 ,5.0610
28 ,7.1610
210 1.4610
23 ,7.7610
213 1.3610
27 3.0610
27 ,7.1610
212 20
hldE ,2.0610
212 ,5.0610
28 7.1610
25 0.8 1.1610
23 3.3610
22 5.6610
26 ,7.1610
212 120
waaF 2.8610
24 ,5.0610
28 3.6610
25 0.6 8.5610
24 0.1 0.2 ,7.1610
212 60
waaL ,2.0610
212 ,5.0610
28 6.4610
23 0.9 0.8 1.9 1.0 1.4 300
wabD 0.9 0.7 1.9 1.2 1.4 1.8 0.7 1.2 90
wabC 1.0 1.0 3.5 1.4 2.0 0.7 1.3 0.9 210
aThe phage plaquing tests were performed at 28uC.
bThe titers of bacteriophages (PFU/ml) determined on CO92 Pgm
2 strain were: 5.0610
11 (L-413C), 2.0610
7 (P2 vir1), 1.4610
9 (QJA1), 5.0610
12 (QA1122), 1.3610
12
(Pokrovskaya), 9.0610
11 (T7Yp), 3.0610
11 (Y), 1.4610
11 (PST), and 1.0610
9 (R).
doi:10.1371/journal.pone.0025486.t004
Table 5. Restoration of phage susceptibility as a result of
trans-complementation of Y. pestis LPS-affected mutants.
Y. pestis
strain
a Susceptibility to
b:
L-413C P2 vir1 QJA1 QA1122 Pokrovskaya T7Yp YP S T
CO92 Pgm
2
(parental)
+ + + + + + + +
yrbH
c 2 2 2 2 2 2 2 2
yrbH (pYrbH
d) + + + + + + + +
waaA 2 2 2 2 2 2 2 2
waaA (pWaaA) + + + + + + + +
hldE 2 2 2 + 2 2 2 2
hldE(pHldE) + + + + + + + +
waaF 2 2 2 + 2 + + 2
waaF (pWaaF) + + + + + + + +
waaL 2 2 2 + + + + +
waaL (pWaaL) + + + + + + + +
aThe phage plaquing tests were performed at 28uC.
b+, phage-susceptible; 2, phage-resistant.
cEach of the mutants was also transformed with a pBAD vector without insert to
exclude possible impact of the vector on LPS structure and phage
susceptibility; all pBAD
+ transformants had the same phenotype as the
parental mutant (data not shown).
dSee characteristics of the recombinant plasmids in Table 1 and Materials and
Methods.
doi:10.1371/journal.pone.0025486.t005
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(HepII) and a terminal outer core residue, b-N-acetyl-D-glucos-
amine (GlcNAc) [51]. Since waaL mutants carried the minimal
LPS outer core defect (lack of GlcNAc) and still lost phage
susceptibility, we concluded that a critical part of the receptor for
L-413C and P2 vir1 is the terminal GlcNAc residue of the LPS
outer core (Fig. 2). This was confirmed by trans-complementation
of waaL mutation with the waaL gene cloned in a pBAD vector,
which resulted in full restoration of susceptibility to L-413C and
P2 vir1 (Fig. S1 and Table 5). Adsorption tests (Table 6) showed
that not only waaL but also waaF mutant was affected in the phage
binding, and hldE mutant completely lost the ability to adsorb to L-
413C and P2 vir1. Thus HepII/HepIII and HepI/Glc residues are
also involved in the formation of L-413C and P2 vir1 receptors
(Fig. 2; the receptor is outlined with bold purple line).
The waaL mutation resulted in reduction of the QJA1 phage
efficiency of plating by more than two logs (Table 4) suggesting
that GlcNAc is involved in QJA1 reception (Fig. 2). Both waaF and
hldE mutants further decreased plaquing efficiency by two more
orders of magnitude (Table 4) and thus HepII/HepIII residues
also take part in the formation of QJA1 receptor. Finally, QJA1 did
not form plaques on the coreless mutants yrbH and waaA providing
at least five log difference in the efficiencies of plating in
comparison with the waaF and hldE mutants. This suggests that
the QJA1 phage receptor includes both LPS outer and inner core
sugars and Kdo/Ko residues form a critical part of the receptor
(Fig. 2).
Using the same approach (see Tables 4, 5, and 6), we localized
five more receptors for six other phages (Table 2 and Fig. 2). Since
WaaA forms both GlcN-Kdo and Kdo-Ko bonds and we did not
mutagenize waaE and waaQ genes, we could not identify a single
sugar residue most critical for phage binding in these cases but
mapped most important receptor components to three different
pairs of adjacent inner core residues, Kdo/Ko (for QA1122 and
QJA1), HepI/Glc (for T7Yp and Y), and HepII/HepIII (for
Pokrovskaya and PST). This was confirmed by trans-complemen-
tation tests with recombinant plasmids carrying the yrbH, waaA,
hldE, and waaF genes (Table 5). The restoration of LPS core with
normal mobility was shown in the complemented mutants (see
Fig. 1).
The adsorption assays (Table 6) confirmed the data of plating
efficiency tests on the most important receptor components and
revealed some additional residues involved in the formation of
phage receptors. For example, the experiments with the QA1122
phage confirmed that Kdo/Ko residues are a critical part of the
receptor: the yrbH mutant lost 78% of its phage binding activity.
Additionally, the hldE mutant showed some decreased QA1122
adsorption, suggesting that HepI/Glc residues are also involved in
the phage reception. The adsorption experiments also allowed us
to expand the receptors for the Pokrovskaya, T7Yp and Y phages
(Table 6 and Fig. 2). The adsorption tests with the QJA1 and PST
phages failed; we could not determine any binding even to Y. pestis
CO92 Pgm
2 strain supposed to contain the intact bacteriophage
receptors. The cause could be a low efficiency binding resulting in
Table 6. Phage adsorption tests on Y. pestis LPS mutants.
Y. pestis strain Average percentage of remaining phage particles (±SD)
L-413C P2 vir1 QA1122 Pokrovskaya T7Yp YR
None (control) 100% 100% 100% 100% 100% 100% 100%
yrbH 100%* 100%* 78.0%(64.9) 100%* 93.2%(66.8) 100%* 44.9% (66.5)
hldE 96.2%(63.7) 92.3%(613.3) 29.3%(62.4) 98.9%(62.1) 82.5%(69.9) 60.5%(64.5) 42.7% (64.0)
waaF 57.3%(68.2) 22.0%(61.5) 9.5%(61.0) 82.1%(66.3) 62.5% (65.3) 43.0%(66.0) 36.8% (64.6)
waaL 63.4%(69.1) 23.1%(62.3) 6.1%(61.2) 12.9%(62.3) 35.0% (62.5) 20.3%(60.8) 35.0% (61.9)
wabC 1.1%(60.2) 0% 6.3%(60.1) 14.4%(63.0) 35.9% (64.2) 10.1%(62.5) 38.5% (64.3)
CO92 (parental) 1.3%(60.3) 0.2%(60.1) 6.7%(60.6) 13.2%(62.7) 34.2% (65.1) 15.2%(63.4) 38.8% (64.2)
*Percentages were rounded to 100% when the number of estimated remaining phage was greater than that remaining in the control.
doi:10.1371/journal.pone.0025486.t006
Figure 1. LPS defects in Y. pestis knockout mutants. 20 ml of deproteinized lysates [74] were loaded on 14% SDS-PAGE, run and stained with
Pro-QH Emerald 300 Lipopolysaccharide Gel Stain Kit (Invitrogen). 1 and 12, CandyCane
TM Glycoprotein Molecular Weight Standards (Invitrogen); 2,
CO92 Pgm
2; 3, CO92 Pgm
2 yrbH, 4, CO92 Pgm
2 lpxM; 5, CO92 Pgm
2 waaA, 6, CO92 Pgm
2 wabC; 7, CO92 Pgm
2 wabD; 8, CO92 Pgm
2 waaL; 9, CO92
Pgm
2 waaF; 10, CO92 Pgm
2 hldE; 11, CO92 Pgm
2 yrbH (pYrbH).
doi:10.1371/journal.pone.0025486.g001
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gation of the bacterial suspensions infected with these two phages.
Our data showed that the receptor for the R phage is located
beyond the LPS core (see Tables 4 and 6 and Fig. 2).
Attenuation of Y. pestis phage-resistant mutants in mice
To determine if bacteriophage resistance mutations impact on
Y. pestis virulence, we reproduced site-directed mutagenesis [68] of
five genes (waaL, waaF, hldE, waaA, and yrbH) in the fully virulent
wild type strain CO92 (Pgm
+) (Table 1). Additionally, eight
spontaneous mutants of CO92 resistant to the L-413C phage were
isolated. All remained susceptible to QA1122. Seven of them
became sensitive to polymyxin B. One Pmx
s (S-2) and one Pmx
r
(S-7) spontaneous mutants were selected for further work. LD50
doses were determined for the two spontaneous and five site-
directed phage-resistant mutants in comparison with the parental
strain CO92 in BALB/c mice after subcutaneous injection (see
Table 7). Six phage-resistant mutants of seven tested (86%) were
shown to be attenuated, with significantly higher LD50 and longer
mean times to death (MTD). Three of them (S-2, yrbH-1, and
waaA-1) completely lost virulence. Only one spontaneous mutant
resistant to L-413C (S-7) was fully virulent. Both yrbH and waaA
mutants lack the LPS outer and inner core ([80]; see also Fig. 1,
lanes 3 and 5) and they both became fully avirulent. The same
results were obtained in a repeated experiment with independently
derived mutants, yrbH-2 and waaA-2 (Table 7).
Figure 2. Identification of Y. pestis cell surface receptors for different bacteriophages. The structure of LPS core is presented according to
[51]. Kdo, 2-keto-3-deoxy-octulosonic acid; Ko, D-glycero-D-talo-oct-2-ulosonic acid; Hep, heptulose (ketoheptose); Glc, glucose; Gal, galactose; GlcNAc,
N-acetylglucosamine. Black dashed lines designate the sites where the gene product, a corresponding glycosyltransferase, forms a glycosidic bond.
The yrbH mutations affecting Kdo synthesis have the same effect on the LPS structure as waaA mutations, and defect in the hldE gene involved in
ADP-L,D-heptose synthesis causes the same phenotype as the waaC mutation [51]. The critical sugar residues for certain phage receptors have solid
color fill matching with that of phage designations and with the color of lines outlining the receptors. The phage receptors are outlined with bold
purple (for the L-413C and P2 phages), dashed red (for QJA1), bold green (for PST), dashed green (for Pokrovskaya), dashed blue (for T7Yp and Y), and
bold red (for QA1122) lines.
doi:10.1371/journal.pone.0025486.g002
Table 7. Attenuation of spontaneous L-413C-resistant and defined LPS-affected mutants for BALB/c mice infected subcutaneously.
Strain LD50 (CFU) Attenuation (fold) Mean time to death (days) MTD extension
CO92 (WT) 3.3 _ 5.5 _
S-2 $9.8610
7 $3.0610
7 .14.0 .150%
S-7 1.7 _ 5.7 _
waaL 44.4 13.5 5.8 _
waaF 4.5610
2 1.4610
2 9.0 64%
hldE 6.3610
3 1.9610
3 11.9 116%
waaA-1 $1.3610
7 $3.9610
6 .14.0 .150%
yrbH-1 $3.4610
7 $1.0610
7 .14.0 .150%
CO92 (WT)* 2.2 _ 5.4 _
waaA-2* $8.0610
6 $3.6610
6 .14.0 .150%
yrbH-2* $9.1610
6 $2.8610
6 .14.0 .150%
*Repeated experiment.
doi:10.1371/journal.pone.0025486.t007
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The emergence of multidrug-resistant strains of Y. pestis [4] may
result in outbreaks of untreatable bubonic and pneumonic plague
with very high mortality and suggests the paramount importance
of finding adequate alternatives to antibiotics including bacterio-
phages [5], which have already shown a high efficacy for the
therapy of several other infections [6–8]. One of the major
problems that can arise when using phages as therapeutics is the
development of phage-resistant mutants [28–30], most frequently
resulting from the alteration or loss of the bacterial cell surface
receptor [31–33]. To solve this problem, one can use therapeutic
cocktails consisting of phages that exploit different bacterial
receptors [29,30,48]. Another way is to use the phages adsorbing
on pathogenicity factors so that the receptor mutations resulting in
phage resistance simultaneously attenuate the bacterium, which is
subsequently eliminated from the host by the immune system
[29,34,35,38]. Given the high potential of bacteriophages as
alternative therapies against drug-resistant plague, here we
addressed the problem of phage-resistant mutants in Y. pestis and
both strategies of its overcoming: identified Y. pestis receptors for a
number of bacteriophages and determined if the phage-resistant
mutants become attenuated.
Nine phages able to lyse Y. pestis were tested. They included four
plague diagnostic phages, L-413C [14,19,23,24,27], QA1122
[10,18,22,25–27], Pokrovskaya [9,14,23,24], and Y [12,13]; two
pseudotuberculosis diagnostic phages also capable of lysing most Y.
pestis strains, PST [12,61–63] and R [12,15,63–65]; as well as P2
vir1, a virulent mutant of well-known coliphage P2 [59] previously
shown to lyse Y. pestis at 37uC [19,27]. Additionally, we isolated a
new Y. pestis-specific phage from sewage, QJA1, and also selected a
host range mutant of enterobacteriophage T7, T7Yp, which
showed both a striking specificity and high lytic activity towards Y.
pestis. First, we demonstrated a significant difference in the
frequencies of spontaneous mutations of Y. pestis resistance to
phages belonging to different morphologic and taxonomic groups.
For example, resistance to L-413C was a rather frequent event
(about 10
24 per cell per generation), whereas we could not isolate
any spontaneous mutants resistant to QA1122, suggesting that
these two phages use different bacterial surface receptors for their
adsorption. Most L-413C-resistant clones became sensitive to
polymyxin B, indicating that they have an LPS core defect [51,76].
All mutants resistant to L-413C remained sensitive to QA1122.
This finding also suggested that L-413C and QA1122 exploit
different surface structures as the receptors.
Site-directed mutagenesis of different LPS genes, mainly those
encoding for glycosyltransferases involved in the synthesis of the
LPS outer and inner core, and trans-complementation with the
cloned genes followed by efficiency of plating and adsorption tests
(Tables 4, 5, 6) allowed us to localize six Y. pestis cell surface
receptors for bacteriophages in different parts of the LPS core
(Fig. 2). It was demonstrated that the terminal residue of the outer
core, N-acetylglucosamine, is a critical part of L-413C and P2 vir1
receptor. The most important parts of the rest of the receptors
were mapped to three different pairs of adjacent Y. pestis LPS inner
core residues, Kdo/Ko (for the QA1122 and QJA1 phages), HepI/
Glc (for T7Yp and Y), and HepII/HepIII (for Pokrovskaya and
PST). Apart from the critical receptor components, we found some
additional LPS sugar residues involved in the phage adsorption
that made up six different receptor structures for eight phages
(Fig. 2). The seventh receptor, for the R phage, was shown to lie
beyond the LPS core.
The location of phage receptors in different LPS core residues
can at least partially explain the difference in the frequencies of
phage resistance mutations. For example, L-413C provided the
highest frequency of resistance, most probably due to the largest
number of genes, mutations in which result in the receptor loss
(waaL, wecA, waaF, waaC, hldE, waaA, yrbH and other genes
responsible for Kdo biosynthesis; see Fig. 2, Refs. 51 and 80). At
the same time, QA1122 binds to Kdo and HepI/Glc residues that
can be affected by mutations in a relatively small number of genes.
Therefore, nine bacteriophages tested in this work can use at
least seven different receptors in Y. pestis. Based on the principle of
formulating optimal therapeutic cocktails from the phages that
employ different cell surface receptors [29,30,48] and on our
results, we recommend six bacteriophages as the best candidates
for a plague therapeutic cocktail: QA1122, Pokrovskaya, Y, T7Yp,
QJA1, and R. They use different receptors in Y. pestis. The best
candidate in this list is the QA1122 phage previously shown to be
rather specific [22,25–27], highly lytic [27] and active against
virtually all known Y. pestis isolates [18,22]. We identified the Y.
pestis receptor for QA1122 and demonstrated that the mutation of
resistance to this phage is a very rare event. There are only two
known Y. pestis strains resistant to QA1122 out of thousands tested
[18]. It is also important that QA1122 genome has been sequenced
and no potentially detrimental genes were found in it [18]. The
Pokrovskaya [14,23,24], Y [12,13], and R [15,63,65] phages have
been shown to be highly active against Y. pestis (especially,
Pokrovskaya and Y) and to have broad ranges of susceptible
strains. Our results provided important new information about the
receptors for these bacteriophages, making them also promising as
potential components of plague therapeutic cocktails. Finally, two
new phage isolates, T7Yp (a coliphage T7 host range mutant) and
QJA1 (obtained from sewage) demonstrate a high specificity and
significant lytic potential towards Y. pestis, particularly, T7Yp (A.A.
Filippov, Y. He, and K.V. Sergueev, unpublished data) and use
known receptors on the bacterial cell surface, which also makes
them good candidates for future plague therapeutic cocktails. For
T7Yp, it is also important that its parental phage, T7, has been
sequenced and no genes potentially harmful for warm-blooded
animals were identified [83].
Determination of median lethal doses in BALB/c mice by
subcutaneous route of administration for two spontaneous Y. pestis
L-413C-resistant mutants and seven defined LPS-affected mutants
resistant to different phages showed that eight of them (89%) were
attenuated, displaying a significant increase in LD50 and MTD
(Table 7). Five mutants (S-2, waaA-1, waaA-2, yrbH-1, and yrbH-2)
became completely avirulent. Only one spontaneous mutant
resistant to L-413C (S-7) that retained polymyxin resistance was
fully virulent. This mutation seems to be unrelated to the phage
receptor, instead affecting some steps of phage lytic cycle following
its adsorption, e.g., DNA replication or phage assembly [31]. The
attenuation of most phage-resistant strains suggests that the
emergence of such mutants in vivo should result in their elimination
by the immune system and thus should not significantly decrease
the efficiency of phage therapy.
Site-directed mutations in each of the three tested genes
encoding for glycosyltransferases that incorporate different sugar
residues into the LPS core (waaA, waaF, and waaL), as well as in
two genes essential for Kdo (yrbH) and ADP-L,D-heptose (hldE)
biosynthesis were shown to affect Y. pestis virulence (Table 7). It has
been previously found that mutants of Yersinia enterocolitica [84],
Salmonella enterica [85], Actinobacillus pleuropneumoniae [86], and
Burkholderia cenocepacia [87] with different LPS core defects
demonstrate reduced virulence. In Y. pestis, in vivo maintenance
of a tetra-acylated structure of lipid A in LPS has been shown to be
essential for mouse virulence after subcutaneous infection [88].
Recently, five LPS core mutants of Y. pestis 231 (biovar Antiqua)
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subcutaneously, wabD, waaL, waaQ, waaE, and hldE [51]. Of them,
waaL and waaE mutants showed a slight increase in LD50 for mice
and guinea pigs, whereas hldE was attenuated by four logs. Our
results on the waaL and hldE mutants are in agreement with the
previous data [51]. Additionally, our data (Table 7) show that
there is a clear correlation between the degree of LPS core
truncation and attenuation. Some spontaneous undefined Y. pestis
mutants resistant to the Pokrovskaya and/or L-413C phages have
been observed to have reduced virulence or to become avirulent
for mice or guinea pigs [77]. Here we showed that the most likely
cause of attenuation of such mutants is the LPS core truncation.
It is important that both yrbH and waaA mutants (two pairs of
independently derived clones) lacking the LPS core [74,80]
demonstrated full avirulence (Table 7). These two types of mutants
have different mechanisms of the loss of LPS core. The waaA
product is a transferase catalyzing Kdo glycosylation of lipid A
[80], while the YrbH protein is arabinose 5-phosphate isomerase
that converts ribulose 5-phosphate into arabinose 5-phosphate,
which is the first committed step in the Kdo biosynthesis [74,80].
The complete loss of virulence in the two types of LPS coreless
mutants suggests that LPS is a critical virulence factor of Y. pestis.
These results are of great importance for the molecular
pathogenesis of plague because previously only the loss of major
components of type III secretion system encoded on the plasmid
pCD1 [89–91], a chromosomal gene cluster of siderophore
yersiniabactin synthesis and reception [91–94] or a gene encoding
for the NlpD lipoprotein [95] have been known to completely
attenuate Y. pestis strains.
Supporting Information
Figure S1 Trans-complementation of L-413C phage
receptor defect. A, B, and C: L-413C plaquing on Y. pestis
CO92 Pgm
2, CO92 Pgm
2 waaL, and CO92 Pgm
2 waaL
(pWaaL), respectively.
(TIF)
Table S1 Primers for mutagenesis of Y. pestis LPS genes and
verifying the sizes of amplicons. Notes:
a50-bp flanking sequences
of Y. pestis chromosomal DNA providing site-specific insertion of
kanamycin cassette are shown in lower case type.
bF1 and R1
primers targeted Y. pestis DNA on the gene flanks and provided
amplification of a fragment with changed size due to the
replacement with the Km
r gene.
cInt (internal) primers amplified
the corresponding intact Y. pestis gene and were used to exclude
gene duplications and emergence of merodiploids.
dThe kan-start
and kan-stop primers targeted the Km
r gene and were used to
amplify the DNA novel joints with corresponding F1 and R1
primers, respectively.
(DOCX)
Table S2 Primers for cloning of Y. pestis LPS genes. Notes:
aTwo
tandem stop codons in the yrbH forward primer are underscored.
Lower case letters in the rest of forward primers designate
modified ribosome binding site according to recommendations of
the supplier of the TOPO cloning system (Invitrogen).
(DOCX)
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